open access
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
Affiliations
- Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsow, Poland
open access
Abstract
Breast cancer remains the most frequent cancer among women in Poland with malignancies, despite significant improvement in early detection and treatment. In oestrogen receptor-positive breast cancers activation of the CDK4/CDK6/E2F axis is very common, and one of the mechanisms of action of the endocrine therapies is the suppression of CDK4 and CDK6 activity. The inhibition of CDKs is an important target for novel agents. This article concentrates on two CDK4/6 inhibitors, which showed promising efficacy in recently published studies: palbociclib and ribociclib. The phase 3 studies with palbociclib and ribociclib produced practice-changing results, improving the progression-free survival in the first-line setting in ER-positive HER2-negative advanced breast cancer when added to standard endocrine therapy.
Abstract
Breast cancer remains the most frequent cancer among women in Poland with malignancies, despite significant improvement in early detection and treatment. In oestrogen receptor-positive breast cancers activation of the CDK4/CDK6/E2F axis is very common, and one of the mechanisms of action of the endocrine therapies is the suppression of CDK4 and CDK6 activity. The inhibition of CDKs is an important target for novel agents. This article concentrates on two CDK4/6 inhibitors, which showed promising efficacy in recently published studies: palbociclib and ribociclib. The phase 3 studies with palbociclib and ribociclib produced practice-changing results, improving the progression-free survival in the first-line setting in ER-positive HER2-negative advanced breast cancer when added to standard endocrine therapy.
Keywords
CDK4/6 inhibitor, breast cancer, palbociclib, ribociclib, abemaciclib
About this articleTitle
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
Journal
Issue
Article type
Review paper
Pages
209-214
Published online
2017-06-02
DOI
10.5603/OCP.2016.0017
Bibliographic record
Oncol Clin Pract 2016;12(6):209-214.
Keywords
CDK4/6 inhibitor
breast cancer
palbociclib
ribociclib
abemaciclib
Authors
Roman Dubiański
Agnieszka Jagiełło-Gruszfeld
Zbigniew Nowecki